-
1
-
-
77649312646
-
(2010) Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population
-
Asukai, Y., Valladares, A., Camps, C., Wood, E., Taipale, K., Arellano, J. et al. (2010) Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. BMC Cancer 10: 26.
-
BMC Cancer
, vol.10
, pp. 26
-
-
Asukai, Y.1
Valladares, A.2
Camps, C.3
Wood, E.4
Taipale, K.5
Arellano, J.6
-
2
-
-
74949133978
-
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for stage IV non-small cell lung cancer
-
Azzoli, C.G., Baker Jr, S., Temin, S., Pao, W., Aliff, T., Brahmer, J. et al. (2009) American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for stage IV non-small cell lung cancer. J Clin Oncol 27: 6251-6266.
-
(2009)
J Clin Oncol
, vol.27
, pp. 6251-6266
-
-
Azzoli, C.G.1
Baker Jr, S.2
Temin, S.3
Pao, W.4
Aliff, T.5
Brahmer, J.6
-
3
-
-
25444511051
-
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer
-
Belani, C.P., Lee, J.S., Socinski, M.A., Robert, F., Waterhouse, D., Rowland, K. et al. (2005) Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 16: 1069-1075.
-
(2005)
Ann Oncol
, vol.16
, pp. 1069-1075
-
-
Belani, C.P.1
Lee, J.S.2
Socinski, M.A.3
Robert, F.4
Waterhouse, D.5
Rowland, K.6
-
4
-
-
33646485007
-
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial
-
Brodowicz, T., Krzakowski, M., Zwitter, M., Tzekova, V., Ramlau, R., Ghilezan, N. et al. (2006) Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 52: 155-163.
-
(2006)
Lung Cancer
, vol.52
, pp. 155-163
-
-
Brodowicz, T.1
Krzakowski, M.2
Zwitter, M.3
Tzekova, V.4
Ramlau, R.5
Ghilezan, N.6
-
5
-
-
70349475409
-
SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC
-
et al., on behalf of the SATURN Investigators (Suppl): Abstract
-
Cappuzzo, F.C.T., Stelmakh, L., Cicenas, S., Szczesna, A., Juhasz, E. and Esteban Gonzalez, E. et al., on behalf of the SATURN Investigators ( 2009) SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 27(Suppl): Abstract 8001.
-
(2009)
J Clin Oncol
, vol.27
, pp. 8001
-
-
Cappuzzo, F.C.T.1
Stelmakh, L.2
Cicenas, S.3
Szczesna, A.4
Juhasz, E.5
Esteban Gonzalez, E.6
-
6
-
-
50849117805
-
Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC)
-
Carlson, J.J., Reyes, C., Oestreicher, N., Lubeck, D., Ramsey, S.D. and Veenstra, D.L. ( 2008) Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 61: 405-415.
-
(2008)
Lung Cancer
, vol.61
, pp. 405-415
-
-
Carlson, J.J.1
Reyes, C.2
Oestreicher, N.3
Lubeck, D.4
Ramsey, S.D.5
Veenstra, D.L.6
-
7
-
-
70350225538
-
(2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small cell lung cancer: a randomised, double-blind, phase 3 study
-
Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J.H., Krzakowski, M., Laack, E. et al. (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374: 1432-1440.
-
Lancet
, vol.374
, pp. 1432-1440
-
-
Ciuleanu, T.1
Brodowicz, T.2
Zielinski, C.3
Kim, J.H.4
Krzakowski, M.5
Laack, E.6
-
8
-
-
77649222572
-
(2010) Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small cell lung cancer: data from the randomized phase III INTEREST trial
-
Douillard, J.Y., Shepherd, F.A., Hirsh, V., Mok, T., Socinski, M.A., Gervais, R. et al. (2010) Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 28: 744-752.
-
J Clin Oncol
, vol.28
, pp. 744-752
-
-
Douillard, J.Y.1
Shepherd, F.A.2
Hirsh, V.3
Mok, T.4
Socinski, M.A.5
Gervais, R.6
-
9
-
-
59149092945
-
(2009) Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer
-
Fidias, P.M., Dakhil, S.R., Lyss, A.P., Loesch, D.M., Waterhouse, D.M., Bromund, J.L. et al. (2009) Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol 27: 591-598.
-
J Clin Oncol
, vol.27
, pp. 591-598
-
-
Fidias, P.M.1
Dakhil, S.R.2
Lyss, A.P.3
Loesch, D.M.4
Waterhouse, D.M.5
Bromund, J.L.6
-
10
-
-
68249134187
-
(2009) How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question
-
Fojo, T. and Grady, C. (2009) How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 101: 1044-1048.
-
J Natl Cancer Inst
, vol.101
, pp. 1044-1048
-
-
Fojo, T.1
Grady, C.2
-
11
-
-
0042413836
-
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group
-
Fossella, F., Pereira, J.R., von Pawel, J., Pluzanska, A., Gorbounova, V., Kaukel, E. et al. (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol 21: 3016-3024.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3016-3024
-
-
Fossella, F.1
Pereira, J.R.2
von Pawel, J.3
Pluzanska, A.4
Gorbounova, V.5
Kaukel, E.6
-
12
-
-
2442661845
-
(2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy
-
Hanna, N., Shepherd, F.A., Fossella, F.V., Pereira, J.R., de Marinis, F., von Pawel, J. et al. (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597.
-
J Clin Oncol
, vol.22
, pp. 1589-1597
-
-
Hanna, N.1
Shepherd, F.A.2
Fossella, F.V.3
Pereira, J.R.4
de Marinis, F.5
von Pawel, J.6
-
13
-
-
56249109644
-
Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomised phase III trial
-
Kim, E.S., Hirsh, V., Mok, T., Socinski, M.A., Gervais, R., Wu, Y.L. et al. (2008) Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372: 1809-1818.
-
(2008)
Lancet
, vol.372
, pp. 1809-1818
-
-
Kim, E.S.1
Hirsh, V.2
Mok, T.3
Socinski, M.A.4
Gervais, R.5
Wu, Y.L.6
-
14
-
-
13844317894
-
EGFR mutation and resistance of non-small cell lung cancer to gefitinib
-
Kobayashi, S., Boggon, T.J., Dayaram, T., Janne, P.A., Kocher, O., Meyerson, M. et al. (2005) EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
-
(2005)
N Engl J Med
, vol.352
, pp. 786-792
-
-
Kobayashi, S.1
Boggon, T.J.2
Dayaram, T.3
Janne, P.A.4
Kocher, O.5
Meyerson, M.6
-
15
-
-
73449117924
-
(2010) Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer
-
Lyseng-Williamson, K.A. (2010) Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer. Pharmaco Economics 28: 75-92.
-
Pharmaco Economics
, vol.28
, pp. 75-92
-
-
Lyseng-Williamson, K.A.1
-
16
-
-
19944413630
-
Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer
-
Martoni, A., Marino, A., Sperandi, F., Giaquinta, S., Di Fabio, F., Melotti, B. et al. (2005) Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 41: 81-92.
-
(2005)
Eur J Cancer
, vol.41
, pp. 81-92
-
-
Martoni, A.1
Marino, A.2
Sperandi, F.3
Giaquinta, S.4
Di Fabio, F.5
Melotti, B.6
-
17
-
-
70349477817
-
A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
-
and for the ATLAS Investigators Abstract LBA8002.
-
Miller, V.A.O.C.P., Soh, C., Kabbinavar, F., and for the ATLAS Investigators ( 2009) A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 27: Abstract LBA8002.
-
(2009)
J Clin Oncol
, vol.27
-
-
Miller, V.A.O.C.P.1
Soh, C.2
Kabbinavar, F.3
-
18
-
-
69949162760
-
(2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N. et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
-
N Engl J Med
, vol.361
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
Yang, C.H.4
Chu, D.T.5
Saijo, N.6
-
19
-
-
84971581087
-
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
-
Non-small Cell Lung Cancer Collaborative Group
-
Non-small Cell Lung Cancer Collaborative Group ( 1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909.
-
(1995)
BMJ
, vol.311
, pp. 899-909
-
-
-
21
-
-
36849019938
-
Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small cell lung cancer
-
Park, J.O., Kim, S.W., Ahn, J.S., Suh, C., Lee, J.S., Jang, J.S. et al. (2007) Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small cell lung cancer. J Clin Oncol 25: 5233-5239.
-
(2007)
J Clin Oncol
, vol.25
, pp. 5233-5239
-
-
Park, J.O.1
Kim, S.W.2
Ahn, J.S.3
Suh, C.4
Lee, J.S.5
Jang, J.S.6
-
22
-
-
1342268525
-
American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003
-
Pfister, D.G., Johnson, D.H., Azzoli, C.G., Sause, W., Smith, T.J., Baker Jr, S. et al. (2004) American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 22: 330-353.
-
(2004)
J Clin Oncol
, vol.22
, pp. 330-353
-
-
Pfister, D.G.1
Johnson, D.H.2
Azzoli, C.G.3
Sause, W.4
Smith, T.J.5
Baker Jr, S.6
-
23
-
-
62449124416
-
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAil
-
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V. et al. (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAil. J Clin Oncol 27: 1227-1234.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1227-1234
-
-
Reck, M.1
von Pawel, J.2
Zatloukal, P.3
Ramlau, R.4
Gorbounova, V.5
Hirsh, V.6
-
24
-
-
69949186250
-
(2009) Screening for epidermal growth factor receptor mutations in lung cancer
-
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C. et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967.
-
N Engl J Med
, vol.361
, pp. 958-967
-
-
Rosell, R.1
Moran, T.2
Queralt, C.3
Porta, R.4
Cardenal, F.5
Camps, C.6
-
25
-
-
16644398719
-
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small cell lung cancer: a phase III randomized study of the London Lung Cancer Group
-
Rudd, R.M., Gower, N.H., Spiro, S.G., Eisen, T.G., Harper, P.G., Littler, J.A. et al. (2005) Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23: 142-153.
-
(2005)
J Clin Oncol
, vol.23
, pp. 142-153
-
-
Rudd, R.M.1
Gower, N.H.2
Spiro, S.G.3
Eisen, T.G.4
Harper, P.G.5
Littler, J.A.6
-
26
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer
-
Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A. et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355: 2542-2550.
-
(2006)
N Engl J Med
, vol.355
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
Brahmer, J.4
Schiller, J.H.5
Dowlati, A.6
-
27
-
-
64049115311
-
(2009) The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies
-
Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P. et al. (2009) The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14: 253-263.
-
Oncologist
, vol.14
, pp. 253-263
-
-
Scagliotti, G.1
Hanna, N.2
Fossella, F.3
Sugarman, K.4
Blatter, J.5
Peterson, P.6
-
28
-
-
0036843105
-
Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer
-
Scagliotti, G.V., de Marinis, F., Rinaldi, M., Crino, L., Gridelli, C., Ricci, S. et al. (2002) Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 20: 4285-4291.
-
(2002)
J Clin Oncol
, vol.20
, pp. 4285-4291
-
-
Scagliotti, G.V.1
de Marinis, F.2
Rinaldi, M.3
Crino, L.4
Gridelli, C.5
Ricci, S.6
-
29
-
-
49049089802
-
(2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer
-
Scagliotti, G.V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C. et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 26: 3543-3551.
-
J Clin Oncol
, vol.26
, pp. 3543-3551
-
-
Scagliotti, G.V.1
Parikh, P.2
von Pawel, J.3
Biesma, B.4
Vansteenkiste, J.5
Manegold, C.6
-
30
-
-
33644684204
-
Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small cell lung cancer: the Swedish Lung Cancer Study Group
-
Sederholm, C., Hillerdal, G., Lamberg, K., Kolbeck, K., Dufmats, M., Westberg, R. et al. (2005) Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 23: 8380-8388.
-
(2005)
J Clin Oncol
, vol.23
, pp. 8380-8388
-
-
Sederholm, C.1
Hillerdal, G.2
Lamberg, K.3
Kolbeck, K.4
Dufmats, M.5
Westberg, R.6
-
31
-
-
22044445517
-
Erlotinib in previously treated non-small cell lung cancer
-
Shepherd, F.A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E.H., Hirsh, V., Thongprasert, S. et al. (2005) Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353: 123-132.
-
(2005)
N Engl J Med
, vol.353
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues Pereira, J.2
Ciuleanu, T.3
Tan, E.H.4
Hirsh, V.5
Thongprasert, S.6
-
32
-
-
0036499649
-
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB / IV non-small cell lung cancer
-
Socinski, M.A., Schell, M.J., Peterman, A., Bakri, K., Yates, S., Gitten, R. et al. (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB / IV non-small cell lung cancer. J Clin Oncol 20: 1335-1343.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1335-1343
-
-
Socinski, M.A.1
Schell, M.J.2
Peterman, A.3
Bakri, K.4
Yates, S.5
Gitten, R.6
-
33
-
-
70249130544
-
(2009) Duration of chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized trials
-
Soon, Y.Y., Stockler, M.R., Askie, L.M. and Boyer, M.J. (2009) Duration of chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 27: 3277-3283.
-
J Clin Oncol
, vol.27
, pp. 3277-3283
-
-
Soon, Y.Y.1
Stockler, M.R.2
Askie, L.M.3
Boyer, M.J.4
-
34
-
-
22044453790
-
Erlotinib in lung cancer - molecular and clinical predictors of outcome
-
Tsao, M.S., Sakurada, A., Cutz, J.C., Zhu, C.Q., Kamel-Reid, S., Squire, J. et al. (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353: 133-144.
-
(2005)
N Engl J Med
, vol.353
, pp. 133-144
-
-
Tsao, M.S.1
Sakurada, A.2
Cutz, J.C.3
Zhu, C.Q.4
Kamel-Reid, S.5
Squire, J.6
-
35
-
-
33750207905
-
(2006) Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small cell lung cancer
-
von Plessen, C., Bergman, B., Andresen, O., Bremnes, R.M., Sundstrom, S., Gilleryd, M. et al. (2006) Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small cell lung cancer. Br J Cancer 95: 966-973.
-
Br J Cancer
, vol.95
, pp. 966-973
-
-
von Plessen, C.1
Bergman, B.2
Andresen, O.3
Bremnes, R.M.4
Sundstrom, S.5
Gilleryd, M.6
-
36
-
-
15944388587
-
Randomized study of maintenance vinorelbine in responders with advanced non-small cell lung cancer
-
Westeel, V., Quoix, E., Moro-Sibilot, D., Mercier, M., Breton, J.L., Debieuvre, D. et al. (2005) Randomized study of maintenance vinorelbine in responders with advanced non-small cell lung cancer. J Natl Cancer Inst 97: 499-506.
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 499-506
-
-
Westeel, V.1
Quoix, E.2
Moro-Sibilot, D.3
Mercier, M.4
Breton, J.L.5
Debieuvre, D.6
|